This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Fero Industries, Inc. Issues Corporate Update

"I am also aggressively working to greatly expand our relationships with pharmaceutical companies around the world. I believe that 2013 will be a breakthrough year for increased exposure of Sucanon into new markets. Our product is the only Type II Diabetes drug with no side effects and high efficacy. This incredible combination of attributes is the key strength of our company."

"In conclusion, I would like to say that we have been working very hard to increase our market penetration in turbulent corporate times. I believe we are now well positioned to move forward as a company in a more aggressive way. I look forward to 2013 and beyond!"

About Sucanon ®

Sucanon ® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers".  Pre-clinical and clinical studies show that Sucanon ® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin.  Sucanon ® has been approved for prescription sale in China and Peru.  Sucanon ® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.

For further information regarding Sucanon ®, please visit the Fero Industries Inc. website at www.feroindustries.com.

About Fero Industries Inc.

Fero Industries, Inc. (OTC: FROI) is focused on diabetes prevention and treatments.  The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon ®, an oral treatment for Type-II diabetes.  Sucanon ® is a member of a class of diabetic medications called insulin sensitizers.  Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin.  Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.  Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon ® globally.

For investor relations contact:

Michael Irving Paramount Advisors, LLC(407) 878-5462

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs